Capricor Therapeutics, Inc. Stockholders with Significant Losses Should Contact Robbins LLP Before the Pending September 28, 2026 Lead Plaintiff Deadline
Robbins LLP is soliciting investors for a securities class action against Capricor Therapeutics covering purchasers of CAPR securities between December 17, 2025 and July 26, 2026, with a September 28, 2026 lead plaintiff deadline. The complaint alleges Capricor misled investors about the FDA approval path for Deramiocel, its lead cell therapy candidate for Duchenne muscular dystrophy, by failing to disclose changes to the pre-specified statistical analysis plan for the Phase 3 HOPE-3 trial and the FDA's disagreement with those changes.
Key figures
- Drug Name
- Deramiocel
- Phase Of Trial
- Phase 3
- Class period
- December 17, 2025 to July 26, 2026
- Fda adcom vote
- non-binding 9-3 vote that available evidence did not support Deramiocel efficacy
- July 27 2026 drop
- approximately 64% ($12.70 per share) to close at $7.00
- July 30 2026 drop
- approximately 36% ($2.38 per share) to close at $4.19
- Class action filed
- Yes
- Lead plaintiff deadline
- September 28, 2026
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.